People carrying a mutant BRCA2 gene are susceptible to breast, ovarian, pancreatic and other tumors. Many facets of BRCA2 have been studied, including its mutation in human cancers, its role in mouse embryogenesis and its RNA expression in dierent tissues and dierent mouse embryogenesis stages. However, there has been very little characterization of BRCA2 protein.
Introduction
Germline mutation of BRCA2 has been shown to predispose carriers to breast and ovarian cancers (Wooster et al., 1995; Tavtigian et al., 1996) . Patients with germline mutations of BRCA2 also have increased risk for many other types of cancer (Phelan et al., 1996; Thorlacius et al., 1996) . As with many other tumor suppressor genes, the wild-type allele of the BRCA2 locus is frequently lost in tumors from patients carrying a mutant BRCA2 allele Berman et al., 1996; Tirkkonen et al., 1997) . In addition, mice homozygous for Brca2 mutations are predisposed to tumors (Connor et al., 1997a; Friedman et al., 1998) . However, somatic mutations of BRCA2, unlike those of most tumor suppressor genes but similar to BRCA1, are rarely found in sporadic breast or ovarian cancers . How inactivation of BRCA2 predisposes patients to tumors is not very clear. The BRCA2 transcript is larger than 10 kb, and its expression has been shown to be cell-cycle regulated Rajan et al., 1996; Vaughn et al., 1996; Wang et al., 1997) . The BRCA2 gene is predicted to encode a protein of 3418 amino acids . The predicted amino acid sequence of BRCA2 does not provide any clue to its function. However, BRCA2 contains several well-conserved BRC repeats (Bork et al., 1996; Bignell et al., 1997) . Recently BRCA2 was shown to associate with RAD51 through these repeated sequences or its carboxyl terminus (Mizuta et al., 1997; Wong et al., 1997) . therefore, BRCA2 is thought to be involved in the RAD51-mediated DNA repair pathway. This suggestion is consistent with the ®nding that mouse embryos with homozygous Brca2 mutations have severe developmental abnormalities (Connor et al., 1997a; Ludwig et al., 1997; Suzuki et al., 1997; Friedman et al., 1998) and that cells from such embryos have increased sensitivity to radiation or DNA-damaging reagents due to a defect in DNA repair (Connor et al., 1997a; Patel et al., 1998) . It has been proposed that BRCA2, like BRCA1 and mismatch repair genes, has à caretaker' rather than`gatekeeper' role in tumorigenesis (Kinzler and Vogelstein, 1997) . The`caretaker' genes are important for maintaining the genome integrity of a cell. Although inactivation of these genes is not required for tumorigenesis, it accelerates the accumulation of genetic alterations required for this process. In addition to BRCA2's role in DNA repair, a fragment of BRCA2 has been shown to have transcription activity (Milner et al., 1997) .
Despite these potential important functions, there has been very little characterization of cellular BRCA2 protein. We therefore investigated the biochemical and biological properties of BRCA2. We discovered that the detection of BRCA2 by immunoblot analysis was sensitive to the temperature used to denature the samples. Using the improved immunoblotting protocol, we showed that BRCA2 was ubiquitously expressed and that its expression was regulated by cell growth.
Results
We generated a monoclonal antibody (N61) against the amino terminal 640 amino acids of BRCA2. In all human cell lines tested except Capan-1, N61 detected a protein at about 400 kDa, which is consistent with the predicted size of wild-type BRCA2. Capan-1 is a pancreatic cancer cell line that has a single base deletion in codon 1982 of BRCA2 . N61 detected a protein of about 230 kDa in Capan-1, a size consistent with the predicted size of the truncated protein expressed from the mutant BRCA2. These results strongly suggested that the protein detected by N61 was the cellular BRCA2. However, the band of the presumable BRCA2 was very weak, required prolonged autoradiography to detect it, and was not much more intense than the nonspeci®c bands detected by this antibody (data not shown).
We then investigated how to improve the detection of BRCA2 by immunoblot analysis. We found that the ability to detect this protein was sensitive to the temperature used to denature the sample. BRCA2 (wild-type or mutant) was the major immunoreactive band and was easily detectable with N61 when cell lysates were denatured at 558C before electrophoresis. The BRCA2 level was signi®cantly lower when lysates were denatured at 998C for 10 min. In contrast, there was no signi®cant dierence in BRCA1 or b-catenin levels between lysates heated at 558C and those heated at 998C (Figure 1 ).
We examined whether the temperature sensitivity in the detection of BRCA2 by immunoblotting was speci®c to N61. Ab-2 (Oncogene Research) and 66066E (Pharmingen) are polyclonal antibodies that react with the carboxyl terminus and the middle region, respectively, of the wild-type BRCA2. Used at the highest recommended concentrations, both these antibodies weakly detected in human cell lines carrying wild-type BRCA2 a protein of 400 kDa that comigrated with the one detected by N61. Ab-2 did not detect the truncated BRCA2 in Capan-1 because the mutant protein lacks the Ab-2 epitope. Although the truncated BRCA2 expressed in Capan-1 should have been detected by 66066E, a comigrating nonspeci®c protein precluded its detection ( Figure 2a ). When we performed immunoblot analysis of cell lysates heated at 998C, the BRCA2 levels detected by these antibodies were signi®cantly reduced ( Figure 2b and data not shown). These results showed that the temperature sensitivity in the detection of BRCA2 by immunoblotting was not speci®c to N61 and suggested that this temperature sensitivity was an intrinsic property of BRCA2.
Using denaturation at 558C, we investigated the tissue spectrum of BRCA2 expression. We found that BRCA2 was present in every human cell line examined (Figure 3 ). In addition to the cell lines shown here, we also detected BRCA2 in the human ovarian cancer cell line SK-OV-3, the human osteogenic sarcoma cell line U-2 OS, and the human cervical carcinoma cell line HeLa, and in the monkey kidney ®broblast cell line COS-1 (data not shown).
We next examined whether the expression of BRCA2 protein was cell-cycle regulated. We and others had previously shown that the expression of BRCA2 mRNA varied during the cell cycle (Rajan et al., 1996; Vaughn et al., 1996; Wang et al., 1997) . However, the mRNA and protein levels of a gene may not have similar expression patterns because of the translational or post-translational regulation, as in the case of cdc2 gene (Welch and Wang, 1992) . A normal human mammary epithelial cell line, MCF12A and a human breast cancer cell line, MCF7, were used in this experiment. Cells were synchronized by release from serum starvation and harvested at dierent times for preparation of lysates and for cell-cycle determination. The levels of BRCA2 in these lysates were detected by immunoblot analysis with N61. Figure 4 shows the result of analysis of MCF12A cells. The expression of BRCA2 was low when the cells were in the G 0 or G 1 phase and increased signi®cantly when the cells entered S phase. Similar results was obtained when the MCF7 cell line was examined (data not shown). These results showed that the expression of BRCA2 was cell-cycle regulated.
Discussion
One critical ®nding of this study is that the detection of BRCA2 by immunoblot analysis was temperature sensitive. We showed that BRCA2 was easier to detect when cell lysates were denatured at 558C instead of by boiling. There are several possible explanations for this observation. The ®rst is that the epitopes for the antibodies were destroyed when BRCA2 was boiled. This is unlikely because antibodies reacting with very dierent regions of BRCA2 had the same sensitivity. Another possibility is that BRCA2 aggregates upon boiling, and the aggregated BRCA2 does not migrate into the gel and therefore cannot be detected. It is also possible that there is a heat-activated protease with a narrow substrate speci®city that degrades BRCA2 upon boiling. Although the precise mechanism underlying this observation is not clear yet, this ®nding will signi®cantly improve our ability to study BRCA2. This is clearly demonstrated by our characterization of BRCA2 using an immunoblot analysis protocol modi®ed according to this observation.
We also showed that BRCA2 protein was expressed in every human cell lines examined. Although BRCA2 mRNA had been shown to be expressed in many dierent human tissues , the expression of BRCA2 protein had been demonstrated only in a human breast cancer cell line MCF7 (Bertwistle et al., 1997) . We have provided the ®rst evidence that BRCA2 protein is expressed in cell lines derived from a variety of human tissues. This result suggests that BRCA2 may be important for general cell growth and is consistent with the suggestion that BRCA2 participates in DNA repair. This observation also indicates that the function of BRCA2 could be investigated by using a variety of cell lines.
Although N61 was very eective in detecting human BRCA2 by immunoblot analysis, it did not detect a similar protein in two mouse and one rat cell lines (data not shown). This is most likely due to the low identity between the amino acid sequences of human and mouse or rat BRCA2 (Connor et al., 1997b; Sharan and Bradey, 1997; GenBank RNU89653) In addition to detecting wild-type BRCA2, we also detected the truncated BRCA2 protein expressed from the mutant BRCA2 gene in Capan-1 cells. Because Capan-1 is the only cell line known to carry a mutation in BRCA2 , we cannot examine how many other mutant BRCA2 proteins are expressed. However, this result indicates that BRCA2 mutations do not always result in the complete loss of BRCA2 protein. This result and the observation that BRCA2 is ubiquitously expressed raise the possibility of identifying BRCA2 mutations in potential BRCA2 mutant carriers by immunoblot analysis.
That Capan-1 is hemizygous for 6174delT, the common BRCA2 mutation found in Ashkenazi Jews, and that BRCA2 mutation carriers have increased risk for pancreatic cancer strongly suggest that Capan-1 was derived from a person carrying germline 6174delT The cells were ®xed in ethanol and stained with propidium iodide, and their cell-cycle distribution was determined BRCA2 mutation Berman et al., 1996; Neuhausen et al., 1996; Abeliovich et al., 1997; Phelan et al., 1996; Thorlacius et al., 1996) . Genetic studies clearly showed that carriers of this BRCA2 mutation were susceptible to breast, ovarian and a variety of other types of cancer (Berman et al., 1996; Neuhausen et al., 1996; Abeliovich et al., 1997) . However, this truncated BRCA2 is expressed and contains at least six BRC repeats and so potentially can interact with RAD51 through these repeats (Wong et al., 1997; Katagiri et al., 1998) . This result suggests that the association of RAD51 with BRC repeats is not sucient for the tumor suppression activity of BRCA2.
We demonstrated in this study the cell cycleregulated BRCA2 protein expression. Earlier studies of BRCA2 mRNA expression showed that BRCA2 mRNA level was low when cells were growth arrested at G 0 or early G 1 phases of cell cycle by serum starvation. The expression of BRCA2 mRNA increased once cells entered G 1 /S boundary of cell cycle (Rajan et al., 1996; Vaughn et al., 1996; Wang et al., 1997) . However, the mRNA and protein levels of a gene could have dierent expression patterns, as in the case of cdc2 gene (Welch and Wang, 1992) . In this study we demonstrated that the pattern of BRCA2 protein expression during the cell cycle was similar to that of BRCA2 mRNA expression. The BRCA2 protein level was low in cells at G 0 and early G 1 phases of cell cycle and increased as the cells entered S phase. The similar results obtained with two cell lines, one normal and one tumor cell lines (this study and Bertwistle et al., 1997) , indicate that this regulation of BRCA2 expression is a general phenomenon. The diminished expression of BRCA2 in quiescent cells and its elevated expression in proliferating cells is consistent with BRCA2's suggested role in the RAD51-mediated DNA repair pathway and might explain why BRCA2 is important for appropriate embryo development and for tumor suppression. The ubiquitous and cell-cycle regulated expression of BRCA2 indicate that the BRCA2 level in a given tissue is more likely to depend on the proliferation state of that tissue than on the type of tissue. Additional investigation using antibodies that can detect BRCA2 by immunohistochemical method will be necessary to demonstrate this.
Materials and methods

Antibodies
A cDNA fragment encoding the amino-terminal 640 amino acids of BRCA2 was obtained by reverse transcriptionpolymerase chain reaction (PCR) using primers 5'-CGCTCGAGGTAAAAATGCCTATTGGATCC-3' and 5' -GCA AGC TTA TGC AAT AAA CCT GAATCAGC -3'. This fragment was inserted between the XhoI and HindIII sites of pGSTag (Ron and Dressler, 1992) . Several isolated clones of this BRCA2 cDNA fragment were sequenced to identify one that did not contain any nucleotide alterations introduced by PCR. The BRCA2 fusion protein was produced and isolated as previously described (Su et al., 1993) . Immunization of mice with this fusion protein and production of monoclonal antibodies were performed as described previously (Liang et al., 1996) .
Polyclonal anti-BRCA2 antibodies 66066E and Ab-2 were purchased from Pharmingen (San Diego, CA) and Oncogene Research (Cambridge, MA), respectively. These antibodies were generated against amino acids 1323 ± 1346 and 3245 ± 3418, respectively, of BRCA2.
The anti-BRCA1 antibody D1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and the antibody against b-catenin was purchased from Transduction Laboratory (Lexington, KY).
Cell lines
MCF10A and MCF12A are normal breast epithelial cell lines. MCF7 is a breast cancer cell line. Capan-1 and BxPC-3 are pancreatic cancer cell lines. SW480, HT29 and HCT116 are colon cancer cell lines. K562 is a leukemia cell line. All cell lines were obtained from the American Type Culture Collection (Rockville, MD).
Immunoblot analysis
Cells were lysed in RIPA buer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate and 1% Nonidet P-40) containing protease inhibitor (2 mg/ml 4-(2-aminoethyl)benzenesulfonyl¯uoride (Calbiochem, La Jolla, CA) and 0.01 mg/ml each antipain, chymostatin, leupeptin and pepstatin A (all from Sigma Chemical Co., St Louis, MO)). Cell lysates containing 50 ± 150 mg of total protein were heated at 558C, unless otherwise indicated, for 10 min after the addition of an appropriate amount of concentrated Laemmli sample buer. Proteins were resolved on 6% SDS-polyacrylamide gels and then transferred onto Immobilon-P membranes (Millipore Corp., Bedford, MA). The proteins were detected by immunoblot analysis with the antibodies indicated and the ECL or ECL Plus system (Amersham Corp., Arlington Heights, IL).
Synchronization of cell growth and cell cycle analysis
The growth of MCF12A and MCF7 cells were arrested by growth in Dulbecco's modi®ed Eagle's medium/F12 without phenol red or any other supplement for 24 and 48 h, respectively. The cells were released from growth arrest by replacing the serum-free medium with complete medium and were harvested at various times. Lysates were prepared from these synchronized cell population as described. The cell-cycle distribution of the cells was determined by¯ow cytometry analysis as previously described (Wang et al., 1997) . 
